

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM497755

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Wilmington Savings Fund Society, FSB		11/08/2018	Federal Savings Bank:
RECEIVING PARTY DATA			
Name:	Aegerion Pharmaceuticals, Inc.		
Street Address:	One Main Street, Suite 800		
City:	Cambridge		
State/Country:	MASSACHUSETTS		
Postal Code:	02142		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 14			
Property Type	Number	Word Mark	
Serial Number:	87177217	NOVELION THERAPEUTICS	
Serial Number:	87177235	NOVELION THERAPEUTICS	
Registration Number:	5381517	NOVELION THERAPEUTICS	
Registration Number:	5381456	NOVELION THERAPEUTICS	
Registration Number:	5237690	BYMYSIDE	
Registration Number:	5237691	BYMYSIDE	
Registration Number:	5276666	LOWER	
Registration Number:	4607022	MYALEPT	
Registration Number:	4512713	JUXTAPID	
Registration Number:	4508190	JUXTAPID	
Registration Number:	4589120	MYALEPT	
Registration Number:	3977343	AEGERION PHARMACEUTICALS	
Registration Number:	3300046	AEGERION	
Registration Number:	3448427	AEGERION PHARMACEUTICALS, INC.	
CORRESPONDENCE DATA			
Fax Number:	2127288111		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			

CH \$365.00 87177217

Phone: 2127288000
Email: ipdept@willkie.com
Correspondent Name: Shoshana Schoenfeld c/o Willkie Farr & G
Address Line 1: 787 Seventh Avenue
Address Line 4: New York, NEW YORK 10019

ATTORNEY DOCKET NUMBER: 125212.00001 SS

NAME OF SUBMITTER: Shoshana Schoenfeld

SIGNATURE: /Shoshana Schoenfeld/

DATE SIGNED: 11/12/2018

Total Attachments: 6

source=Aegerion - Trademark Release Executed (002)#page1.tif

source=Aegerion - Trademark Release Executed (002)#page2.tif

source=Aegerion - Trademark Release Executed (002)#page3.tif

source=Aegerion - Trademark Release Executed (002)#page4.tif

source=Aegerion - Trademark Release Executed (002)#page5.tif

source=Aegerion - Trademark Release Executed (002)#page6.tif

RELEASE OF SECURITY INTEREST IN TRADEMARKS

This RELEASE OF SECURITY INTEREST IN TRADEMARKS (this "Release"), dated as of November 8, 2018 (the "Effective Date"), is made by Wilmington Savings Fund Society, FSB, as agent for the Lenders (the "Agent"), in favor of Aegerion Pharmaceuticals, Inc., a Delaware corporation (the "Grantor").

WHEREAS, pursuant to that certain Loan and Security Agreement, dated as of March 15, 2018, by and among the Agent, the Grantor, and certain other parties thereto (as amended, amended and restated, or otherwise modified from time to time, the "Security Agreement"), the Grantor granted to the Agent, as agent for the Lenders, a security interest in and to certain collateral;

WHEREAS, pursuant to the Security Agreement, the Grantor executed and delivered a Trademark Security Agreement, dated as of March 29, 2018 (the "Trademark Security Agreement"), for recordal with the United States Patent and Trademark Office;

WHEREAS, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office on April 2, 2018 at Trademark Reel 6345, Frame 0608;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby agrees as follows:

1. Defined Terms. All capitalized terms used, but not otherwise defined herein, shall have the respective meanings ascribed in or otherwise referenced in the Security Agreement or the Trademark Security Agreement, as applicable.
2. Release. The Agent, without representation or warranty of any kind, hereby releases, discharges, terminates, and cancels all of its security interest in and to the Trademark Collateral, including but not limited to the trademarks and trademark applications set forth in Schedule I attached hereto. If and to the extent that the Agent has acquired any right, title, or interest in and to the Trademark Collateral under the Trademark Security Agreement or the Security Agreement, the Agent, without representation or warranty of any kind, hereby re-transfers, re-conveys, and re-assigns such right, title, or interest to the Grantor. The Agent authorizes and requests that this Release be recorded at the United States Patent and Trademark Office.
3. Termination. The Agent, without representation or warranty of any kind, terminates and cancels the Trademark Security Agreement.
4. Further Assurances. The Agent agrees to take all further actions, and provide to the Grantor and its successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), reasonably requested by the Grantor, to more fully and effectively effectuate the purposes of this Release.

5. Counterparts. This Release may be executed in any number of counterparts and by different parties hereto on separate counterpart signature pages, each constituting an original, but all together one and the same instrument. The Grantor acknowledges that this Release is and shall be effective upon execution and delivery by the parties hereto. Delivery of an executed counterpart of a signature page of this Release by telecopier or other electronic transmission (PDF or TIFF format) shall be effective as delivery of a manually executed counterpart of this Release.


6. Severability. In the event and to the extent that any provision hereof shall be deemed to be invalid or unenforceable by reason of the operation of any law or by reason of the interpretation placed thereon by any court, this Release shall to such extent be construed as not containing such provision, but only as to such locations where such law or interpretation is operative, and the invalidity or unenforceability of such provision shall not affect the validity of any remaining provisions hereof, and any and all other provisions hereof which are otherwise lawful and valid shall remain in full force and effect.

7. Governing Law. This Release and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of, or relating to this Release and the transactions contemplated hereby shall be governed by, and construed in accordance with and governed exclusively by the laws of the State of New York, without regard to conflicts of law or choice of law principles.

[Signature pages follow]

IN WITNESS WHEREOF, the Agent has caused this Release to be executed by its duly authorized representative as of the Effective Date:

**WILMINGTON SAVINGS FUND SOCIETY,
FSB**, not in its individual capacity, solely as Agent

By: 

Name:

Title:

Raye D. Goldsborough
Assistant Vice President

[Signature page to Release of Security Interests in Trademarks]

TRADEMARK
REEL: 006479 FRAME: 0942

GRANTOR:














AEGERION PHARMACEUTICALS, INC.


By: *Barbara Chan*
Name: Barbara Chan
Title: President

[Signature page to Release of Security Interests in Trademarks]

TRADEMARK
REEL: 006479 FRAME: 0943

SCHEDULE 1
TRADEMARKS

Trademark	Image	Source	Application Number	Registration Number	Application Date	Registration Date	Owner Name
NOVELION THERAPEUTICS		US	87177217		20-SEP-2016		Aegerion Pharmaceuticals, Inc.
NOVELION THERAPEUTICS		US	87177235		20-SEP-2016		Aegerion Pharmaceuticals, Inc.
NOVELION THERAPEUTICS		US	87072521	5381517	15-JUN-2016	16-JAN-2018	Aegerion Pharmaceuticals, Inc.
NOVELION THERAPEUTICS		US	87043469	5381456	19-MAY-2016	16-JAN-2018	Aegerion Pharmaceuticals, Inc.
BYMYSIDE		US	86786368	5237690	13-OCT-2015	04-JUL-2017	Aegerion Pharmaceuticals, Inc.
BYMYSIDE		US	86786387	5237691	13-OCT-2015	04-JUL-2017	Aegerion Pharmaceuticals, Inc.
LOWER		US	86235722	5276666	28-MAR-2014	29-AUG-2017	Aegerion Pharmaceuticals, Inc.
MYALEPT		US	86043958	4607022	21-AUG-2013	16-SEP-2014	Aegerion Pharmaceuticals, Inc.
JUXTAPID		US	85981114	4512713	22-FEB-2013	08-APR-2014	Aegerion Pharmaceuticals, Inc.
JUXTAPID		US	85980934	4508190	14-DEC-2012	01-APR-2014	Aegerion Pharmaceuticals, Inc.
MYALEPT		US	85484675	4589120	01-DEC-2011	19-AUG-2014	Aegerion Pharmaceuticals, Inc.
AEGERION PHARMACEUTICALS		US	85162494	3977343	27-OCT-2010	14-JUN-2011	Aegerion Pharmaceuticals, Inc.
AEGERION		US	78906083	3300046	12-JUN-2006	25-SEP-2007	Aegerion Pharmaceuticals, Inc.

AEGERION PHARMACEUTI CALS, INC. (& SWOOSH DESIGN)		US	77283527	3448427	19-SEP- 2007	17-JUN- 2008	Aegerion Pharmaceuticals, Inc.
---	---	----	----------	---------	-----------------	-----------------	--------------------------------------